<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39465901</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.</ArticleTitle><Pagination><StartPage>e70030</StartPage><MedlinePgn>e70030</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70030</ELocationID><Abstract><AbstractText>We aimed to investigate the immune responses to homologous and heterologous COVID-19 booster vaccinations in renal transplant recipients (RTRs) and to identify factors affecting these responses. In this prospective multicenter observational study, we measured the antibody kinetics of 90 RTRs using the chemiluminescent microparticle immunoassay method. The mean age of participants was 45.2 ± 11.4 years, with 35.6% being female. On the 42nd day after the first vaccine dose, the median antibody level was 16.7 (IQR 2.5-249.5) AU/mL, and the seropositivity rate was 60% (n = 36). Mycophenolic acid (MFA) (OR: 0.087, 95% CI: 0.024-0.311) and ACE inhibitor use (OR: 0.203, 95% CI: 0.052-0.794) were identified as independent factors affecting seropositivity. Patients who received the Pfizer/BioNTech booster had significantly higher antibody levels compared to those who received the CoronaVac/Sinovac booster (p = 0.021). Additionally, a significantly higher rate of COVID-19 positivity was observed among patients who received the CoronaVac/Sinovac booster (p = 0.031). Heterologous COVID-19 booster vaccination is significantly more effective than homologous inactivated booster vaccination in enhancing immune responses and preventing new infections in RTRs. MFA and ACE inhibitor usage were independent factors affecting seropositivity. Additional COVID-19 vaccine doses are needed in this patient group.</AbstractText><CopyrightInformation>Journal of Medical Virology© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Yesim</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3006-4112</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasar</LastName><ForeName>Emre</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8271-1831</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozturk</LastName><ForeName>Erensu</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakan</LastName><ForeName>Mine Sebnem</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helvaci</LastName><ForeName>Ozant</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-1382-2439</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozger</LastName><ForeName>Hasan Selcuk</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0003-3894-0092</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cemre Araz</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Materials Science and Nanotechnology, Neuroscience Interdisciplinary Program, UNAM-National Nanotechnology Research Center, Bilkent University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Pinar Aysert</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-8737-9110</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dikmen</LastName><ForeName>Asiye Ugras</ForeName><Initials>AU</Initials><AffiliationInfo><Affiliation>Department of Public Health, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caglar</LastName><ForeName>Kayhan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dizbay</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derici</LastName><ForeName>Ulver</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guz</LastName><ForeName>Galip</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>This study was supported by Gazi Üniversitesi.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="Y">Transplant Recipients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE inhibitor</Keyword><Keyword MajorTopicYN="N">booster vaccine</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">mycophenolic acid</Keyword><Keyword MajorTopicYN="N">renal transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>8</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39465901</ArticleId><ArticleId IdType="doi">10.1002/jmv.70030</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>“Considerations for Implementing and Adjusting Public Health and Social Measures in the Context of COVID‐19 Interim Guidance,” WHO, 2023, https://www.who.int/publications/i/item/who-2019-ncov-adjusting-ph-measures-2023.1.</Citation></Reference><Reference><Citation>K. J. Jager, A. Kramer, N. C. Chesnaye, et al., “Results From the ERA‐EDTA Registry Indicate a High Mortality Due to COVID‐19 in Dialysis Patients and Kidney Transplant Recipients Across Europe,” Kidney International 98, no. 6 (December 2020): 1540–1548, https://doi.org/10.1016/j.kint.2020.09.006.</Citation></Reference><Reference><Citation>E. J. Williamson, A. J. Walker, K. Bhaskaran, et al., “Factors Associated With COVID‐19‐Related Death Using OpenSAFELY,” Nature 584 (2020): 430–436, https://doi.org/10.1038/s41586-020-2521-4.</Citation></Reference><Reference><Citation>N. Scanlon, Y. Saklawi, and N. Rouphael, “The Role of Systems Vaccinology in Understanding the Immune Defects to Vaccination in Solid Organ Transplant Recipients,” Frontiers in Immunology 11 (2020): 582201, https://doi.org/10.3389/fimmu.2020.582201.</Citation></Reference><Reference><Citation>M. R. Iryaningrum, A. Cahyadi, F. A. Damara, R. Bandiara, and M. B. H. Marbun, “Seroconversion Rates in Kidney Transplant Recipients Following SARS‐CoV‐2 Vaccination and Its Association With Immunosuppressive Agents: A Systematic Review and Meta‐Analysis,” Clinical and Experimental Vaccine Research 12, no. 1 (January 2023): 13–24, https://doi.org/10.7774/cevr.2023.12.1.13.</Citation></Reference><Reference><Citation>R. D. Kirkcaldy, B. A. King, and J. T. Brooks, “COVID‐19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions,” JAMA 323 (2020): 2245, https://doi.org/10.1001/jama.2020.7869.</Citation></Reference><Reference><Citation>H. Dheir, A. Tocoglu, H. Toptan, et al., “Short and Mid‐Term SARS‐CoV‐2 Antibody Response After Inactivated COVID‐19 Vaccine in Hemodialysis and Kidney Transplant Patients,” Journal of Medical Virology 94, no. 7 (July 2022): 3176–3183, https://doi.org/10.1002/jmv.27714.</Citation></Reference><Reference><Citation>M. D. Tanriover, H. L. Doğanay, M. Akova, et al., “Efficacy and Safety of an Inactivated Whole‐Virion SARS‐CoV‐2 Vaccine (CoronaVac): Interim Results of a Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Trial in Turkey,” Lancet 398, no. 10296 (July 2021): 213–222, https://doi.org/10.1002/jmv.27714.</Citation></Reference><Reference><Citation>F. P. Polack, S. J. Thomas, N. Kitchin, et al., “Safety and Efficacy of the BNT162b2 mRNA Covid‐19 Vaccine,” New England Journal of Medicine 383, no. 27 (December 2020): 2603–2615, https://doi.org/10.1056/NEJMoa2034577.</Citation></Reference><Reference><Citation>Agencies of the Republic of Turkey Ministry of Health Turkey Medicine and Medical Device Institution. “Türkiye's Medicines and Medical Devices Agency has given emergency use approval to Coronavac,” accessed July 14, 2023, https://www.titck.gov.tr/haber/kamuoyunun-dikkatine-13012021185623.</Citation></Reference><Reference><Citation>Agencies of Turkish Radio and Television Corporation. “The Biontech vaccine has begun to be administered,” accessed September 2, 2023, https://www.trthaber.com/haber/gundem/biontech-asisi-uygulanmaya-baslandi-569556.html.</Citation></Reference><Reference><Citation>“COVID‐19 (SARS‐CoV‐2 Infection) Laboratory Biosafety Guide,” T.R. Ministry of Health, 2020, https://shgmtetkikdb.saglik.gov.tr/TR-65016/covid-19-sars-cov-2-enfeksiyonu-laboratuvar-biyoguvenlik-rehberi.html.</Citation></Reference><Reference><Citation>“Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated With Coronavirus Disease 2019 (COVID‐19),” CDC, 2021, https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html.</Citation></Reference><Reference><Citation>Y. Yildiz, H. S. Ozger, E. Senol, et al., “Evaluation of Long‐Term Antibody Kinetics in Healthcare Workers Vaccinated With Inactivated COVID‐19 Vero Cell Vaccine (CoronaVac), a Propensity Score‐Matched Observational Study,” International Journal of Infectious Diseases 122 (September 2022): 99–106, https://doi.org/10.1016/j.ijid.2022.05.007.</Citation></Reference><Reference><Citation>S. Stai, G. Lioulios, M. Christodoulou, E. Kasimatis, A. Fylaktou, and M. Stangou, “COVID‐19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation,” Life 12, no. 9 (August 2022): 1358, https://doi.org/10.3390/life12091358.</Citation></Reference><Reference><Citation>C. Liu, J. Lee, C. Ta, et al., “Risk Factors Associated With SARS‐CoV‐2 Breakthrough Infections in Fully mRNA‐Vaccinated Individuals: Retrospective Analysis,” JMIR Public Health and Surveillance 8, no. 5 (May 2022): e35311, https://doi.org/10.2196/35311.</Citation></Reference><Reference><Citation>D. Sauré, M. O'Ryan, J. P. Torres, M. Zuniga, E. Santelices, and L. J. Basso, “Dynamic IgG Seropositivity After Rollout of CoronaVac and BNT162b2 COVID‐19 Vaccines in Chile: A Sentinel Surveillance Study,” Lancet Infectious Diseases 22, no. 1 (January 2022): 56–63, https://doi.org/10.1016/S1473-3099(21)00479-5.</Citation></Reference><Reference><Citation>S. A. Costa Clemens, L. Weckx, R. Clemens, et al., “Heterologous Versus Homologous COVID‐19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID‐19 Vaccine in Brazil (RHH‐001): A Phase 4, Non‐Inferiority, Single Blind, Randomised Study,” Lancet 399, no. 10324 (February 2022): 521–529, https://doi.org/10.1016/S0140-6736(22)00094-0.</Citation></Reference><Reference><Citation>M. Seija, F. Rammauro, J. Santiago, et al., “Comparison of Antibody Response to SARS‐CoV‐2 After Two Doses of Inactivated Virus and BNT162b2 mRNA Vaccines in Kidney Transplant,” Clinical Kidney Journal 15, no. 3 (December 2021): 527–533, https://doi.org/10.1093/ckj/sfab291.</Citation></Reference><Reference><Citation>M. Kantauskaite, L. Müller, T. Kolb, et al., “Intensity of Mycophenolate Mofetil Treatment Is Associated With an Impaired Immune Response to SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients,” American Journal of Transplantation 22, no. 2 (February 2022): 634–639, https://doi.org/10.1111/ajt.16851.</Citation></Reference><Reference><Citation>S. C. Frölke, P. Bouwmans, A. L. Messchendorp, et al., “Predictors of Nonseroconversion to SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients,” Transplantation Direct 8, no. 11 (October 2022): e1397, https://doi.org/10.1097/TXD.0000000000001397.</Citation></Reference><Reference><Citation>H. Kai and M. Kai, “Interactions of Coronaviruses With ACE2, Angiotensin II, and R.A.S. Inhibitors‐Lessons From Available Evidence and Insights Into COVID‐19,” Hypertension Research 43, no. 7 (July 2020): 648–654, https://doi.org/10.1038/s41440-020-0455-8.</Citation></Reference><Reference><Citation>A. E. Zemlin and O. J. Wiese, “Coronavirus Disease 2019 (COVID‐19) and the Renin‐Angiotensin System: A Closer Look at Angiotensin‐Converting Enzyme 2 (ACE2),” Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 57, no. 5 (September 2020): 339–350, https://doi.org/10.1177/0004563220928361.</Citation></Reference><Reference><Citation>G. Zhang, Y. Wu, R. Xu, and X. Du, “Effects of Renin‐Angiotensin‐Aldosterone System Inhibitors on Disease Severity and Mortality in Patients With COVID‐19: A Meta‐Analysis,” Journal of Medical Virology 93, no. 4 (April 2021): 2287–2300, https://doi.org/10.1002/jmv.26695.</Citation></Reference><Reference><Citation>M. Montanari, B. Canonico, E. Nordi, et al., “Which Ones, When and Why Should Renin‐Angiotensin System Inhibitors Work Against COVID‐19?,” Advances in Biological Regulation 81 (August 2021): 100820, https://doi.org/10.1016/j.jbior.2021.100820.</Citation></Reference><Reference><Citation>T. Thomson, M. Prendecki, S. Gleeson, et al., “Immune Responses Following 3rd and 4th Doses of Heterologous and Homologous COVID‐19 Vaccines in Kidney Transplant Recipients,” EClinicalMedicine 53 (November 2022): 101642, https://doi.org/10.1016/j.eclinm.2022.101642.</Citation></Reference><Reference><Citation>“COVID‐19 Vaccines in the US,” CDC, accessed August 2, 2023, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.</Citation></Reference><Reference><Citation>R. Link‐Gelles, A. A. Ciesla, K. E. Fleming‐Dutra, et al., “Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, September to November 2022,” MMWR. Morbidity and Mortality Weekly Report 71 (2022): 1526–1530, https://doi.org/10.15585/mmwr.mm7148e1.</Citation></Reference><Reference><Citation>“Stay Up to Date With COVID‐19 Vaccines,” CDC, accessed June 12, 2023, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html.</Citation></Reference><Reference><Citation>A. Britton, P. J. Embi, M. E. Levy, et al., “Effectiveness of COVID‐19 mRNA Vaccines Against COVID‐19–Associated Hospitalizations Among Immunocompromised Adults During SARS‐CoV‐2 Omicron Predominance—Vision Network, 10 States, December 2021–August 2022,” MMWR. Morbidity and Mortality Weekly Report 71 (2022): 1335–1342, https://doi.org/10.15585/mmwr.mm7142a4.</Citation></Reference><Reference><Citation>H. Dheir, A. Tocoglu, H. Toptan, et al., “Short and Mid‐Term SARS‐CoV‐2 Antibody Response After Inactivated COVID‐19 Vaccine in Hemodialysis and Kidney Transplant Patients,” Journal of Medical Virology 94, no. 7 (July 2022): 3176–3183, https://doi.org/10.1002/jmv.27714.</Citation></Reference><Reference><Citation>S. Thotsiri, R. Sittiudomsuk, N. Sutharattanapong, S. Kantachuvesiri, and P. Wiwattanathum, “The Effect of a Booster Dose mRNA Vaccine on COVID‐19 Infection in Kidney Transplant Recipients After Inactivated or Viral Vector Vaccine Immunization,” Vaccines 10, no. 10 (October 2022): 1690, https://doi.org/10.3390/vaccines10101690.</Citation></Reference><Reference><Citation>Y. Yildiz, H. S. Ozger, A. Acar, et al., “The Impact of Vaccination Among Hospitalized Patients With the Diagnosis of Covid‐19,” Infectious Diseases and Clinical Microbiology 5 (2023): 118–126, https://doi.org/10.36519/idcm.2023.216.</Citation></Reference><Reference><Citation>M. Wichaidit, T. Nopsopon, K. Sunan, et al., “Breakthrough Infections, Hospital Admissions, and Mortality After Major COVID‐19 Vaccination Profiles: A Prospective Cohort Study,” Lancet Regional Health‐Southeast Asia 8 (January 2023): 100106, https://doi.org/10.1016/j.lansea.2022.100106.</Citation></Reference><Reference><Citation>Q. Peng, R. Zhou, Y. Wang, et al., “Waning Immune Responses Against SARS‐CoV‐2 Variants of Concern Among Vaccinees in Hong Kong,” EBioMedicine 77 (March 2022): 103904, https://doi.org/10.1016/j.ebiom.2022.103904.</Citation></Reference><Reference><Citation>“People Who Are Immunocompromised,” CDC, accessed June 12, 2023, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html.</Citation></Reference><Reference><Citation>E. Tavukcuoglu, H. Yanik, M. Parveen, et al., “Human Memory T Cell Dynamics After Aluminum‐Adjuvanted Inactivated Whole‐Virion SARS‐CoV‐2 Vaccination,” Scientific Reports 13, no. 1 (March 2023): 4610, https://doi.org/10.1038/s41598-023-31347-8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>